Retail

Walgreen Earnings Follow Better Same-Store Sales

Walgreens_logo
courtesy of Walgreen
Walgreen Co. (NYSE: WAG) posted fourth-quarter and fiscal-year 2013 results before markets opened Tuesday morning. The drugstore chain reported adjusted diluted earnings per share (EPS) of $0.73 on revenues of $17.94 billion. In the same period a year ago, Walgreen reported EPS of $0.63 on revenue of $17.07 billion. Fourth-quarter results also compare to the consensus estimates for EPS of $0.72 and $17.95 billion in revenue.

For the full year, Walgreen’s sales totaled $72.22 billion, compared with $71.63 billion in fiscal 2012. EPS totaled $3.12, compared with a year-ago total of $2.93. The consensus estimates called for EPS of $3.12 on revenues of $72.23 billion.

Walgreen did not offer guidance in its earnings release, but the company’s CEO did have this to say about the future:

Looking ahead, we begin the new fiscal year well positioned to build on the momentum we have coming out of a solid fourth quarter. We are advancing our key strategies with a continued focus on disciplined execution, and are addressing the challenges ahead in a difficult consumer environment and changing health care system.

The consensus first-quarter 2014 forecast calls for EPS of $0.76 on revenues of $18.28 billion. For the full 2014 fiscal year, the consensus estimates call for EPS of $3.54 on revenues of $75.66 billion.

In June of last year, Walgreen paid $6.7 billion for a 45% stake in Alliance Boots, the world’s largest pharmacy-led health and beauty group. At the time, Walgreen said it expected combined synergies to reach $100 million to $150 million in the first year of the partnership. The actual outcome was $154 million, and Alliance Boots contributed $0.08 per share to fourth quarter EPS.

Walgreen also said last June that it expected the partnership to add $0.23 to $0.27, excluding transaction costs, to first-year EPS. It is a bit difficult to tease out the actual amount from the reconciliation of non-GAAP financial measures, but the actual result appears to be worse than that.

Prescription sales rose 6.1% year-over-year in the fourth quarter, and same-store prescription sales rose 6.4%. Prescription sales accounted for 63.9% of total sales in the quarter. Gross margins rose 60 basis points, to 28.9%, as a result of an increase in sales of generic prescription drugs.

Shares are down fractionally in premarket trading this morning, at $53.34 in a 52-week range of $31.88 to $56.84. Thomson Reuters had a consensus analyst price target of around $54.30 before today’s results were announced.

Credit Card Companies Are Doing Something Nuts

Credit card companies are at war. The biggest issuers are handing out free rewards and benefits to win the best customers.

It’s possible to find cards paying unlimited 1.5%, 2%, and even more today. That’s free money for qualified borrowers, and the type of thing that would be crazy to pass up. Those rewards can add up to thousands of dollars every year in free money, and include other benefits as well.

We’ve assembled some of the best credit cards for users today.  Don’t miss these offers because they won’t be this good forever.

Flywheel Publishing has partnered with CardRatings for our coverage of credit card products. Flywheel Publishing and CardRatings may receive a commission from card issuers.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.